Last reviewed · How we verify
Placebo matching OCS capsules
This is a placebo control formulation designed to match the appearance and administration route of an active oral corticosteroid (OCS) comparator in clinical trials.
At a glance
| Generic name | Placebo matching OCS capsules |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo matching capsules contain inert ingredients formulated to be indistinguishable from active OCS medications in Phase 3 trials. They serve as the control arm to assess the efficacy and safety of the active comparator drug, allowing for blinded study design and elimination of bias in patient and investigator assessments.
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma (PHASE3)
- Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo matching OCS capsules CI brief — competitive landscape report
- Placebo matching OCS capsules updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI